Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Massimo Breccia

Showing results (51-60 of 427) with videos related to

Pageof 43
Sort By:
Current Opinion in Hematology|January 18, 2014
ATRA + ATO: has a new standard of care been established in low-risk acute promyelocytic leukaemia?Massimo Breccia, Laura Cicconi, Francesco Lo-Coco
Expert Review of Hematology|April 28, 2015
Improvement of bone marrow fibrosis with ruxolitinib: will this finding change our perception of the drug?Massimo Breccia, Matteo Molica, Gioia Colafigli, et al.
Expert Opinion on Investigational Drugs|June 16, 2021
Asciminib: an investigational agent for the treatment of chronic myeloid leukemiaMassimo Breccia, Gioia Colafigli, Emilia Scalzulli, et al.
Blood Reviews|April 8, 2020
Therapeutic strategies in low and high-risk MDS: What does the future have to offer?Emilia Scalzulli, Sara Pepe, Gioia Colafigli, et al.
Expert Opinion on Drug Safety|January 23, 2016
Adverse events associated with tyrosine kinase inhibitors for the treatment of chronic myeloid leukemiaMassimo Breccia, Gioia Colafigli, Matteo Molica, et al.
Expert Opinion on Pharmacotherapy|May 28, 2016
How has treatment changed for blast phase chronic myeloid leukemia patients in the tyrosine kinase inhibitor era? A review of efficacy and safetySalvatore Perrone, Fulvio Massaro, Giuliana Alimena, et al.
British Journal of Haematology|August 31, 2019
A journey through infectious risk associated with ruxolitinibEmanuela Sant'Antonio, Massimiliano Bonifacio, Massimo Breccia, et al.
Journal of Clinical Medicine|February 4, 2021
Dose Optimization of Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia: A New Therapeutic ChallengeAlessandra Iurlo, Daniele Cattaneo, Cristina Bucelli, et al.
Expert Review of Hematology|March 10, 2018
Novel tyrosine-kinase inhibitors for the treatment of chronic myeloid leukemia: safety and efficacyFulvio Massaro, Gioia Colafigli, Matteo Molica, et al.
Oncotargets and Therapy|April 10, 2013
Systematic review of dasatinib in chronic myeloid leukemiaMassimo Breccia, Adriano Salaroli, Matteo Molica, et al.
Pageof 43

Showing results (51-60 of 427) with videos related to

Sort By:
Pageof 43
Current Opinion in Hematology|January 18, 2014
ATRA + ATO: has a new standard of care been established in low-risk acute promyelocytic leukaemia?Massimo Breccia, Laura Cicconi, Francesco Lo-Coco
Expert Review of Hematology|April 28, 2015
Improvement of bone marrow fibrosis with ruxolitinib: will this finding change our perception of the drug?Massimo Breccia, Matteo Molica, Gioia Colafigli, et al.
Expert Opinion on Investigational Drugs|June 16, 2021
Asciminib: an investigational agent for the treatment of chronic myeloid leukemiaMassimo Breccia, Gioia Colafigli, Emilia Scalzulli, et al.
Blood Reviews|April 8, 2020
Therapeutic strategies in low and high-risk MDS: What does the future have to offer?Emilia Scalzulli, Sara Pepe, Gioia Colafigli, et al.
Expert Opinion on Drug Safety|January 23, 2016
Adverse events associated with tyrosine kinase inhibitors for the treatment of chronic myeloid leukemiaMassimo Breccia, Gioia Colafigli, Matteo Molica, et al.
Expert Opinion on Pharmacotherapy|May 28, 2016
How has treatment changed for blast phase chronic myeloid leukemia patients in the tyrosine kinase inhibitor era? A review of efficacy and safetySalvatore Perrone, Fulvio Massaro, Giuliana Alimena, et al.
British Journal of Haematology|August 31, 2019
A journey through infectious risk associated with ruxolitinibEmanuela Sant'Antonio, Massimiliano Bonifacio, Massimo Breccia, et al.
Journal of Clinical Medicine|February 4, 2021
Dose Optimization of Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia: A New Therapeutic ChallengeAlessandra Iurlo, Daniele Cattaneo, Cristina Bucelli, et al.
Expert Review of Hematology|March 10, 2018
Novel tyrosine-kinase inhibitors for the treatment of chronic myeloid leukemia: safety and efficacyFulvio Massaro, Gioia Colafigli, Matteo Molica, et al.
Oncotargets and Therapy|April 10, 2013
Systematic review of dasatinib in chronic myeloid leukemiaMassimo Breccia, Adriano Salaroli, Matteo Molica, et al.
Pageof 43